Breaking News, Collaborations & Alliances

Depixus, Daiichi Sankyo Partner on MAGNA Technology

Daiichi will use MAGNA to explore the interactions of lead molecules with a number of undisclosed RNA targets.

Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA technology to accelerate Daiichi’s RNA-targeted drug discovery program. Based on magnetic force spectroscopy, MAGNA is a technology that enables high-throughput analysis of dynamic biomolecular interactions in real time with single-molecule resolution. For RNA these insights reveal how small molecules and proteins bind to three-dimensional RNA structures and provide valuable information about binding kineti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters